Aware of the importance of a mutation-specific approach in optimizing therapy for CF patients, researchers have increasingly focused their studies on the characterization of the effect of VX-445, either alone or in combination with VX-770 and VX-661, on the biochemical and functional properties of rare CFTR mutations. This evidence concerns the gene CFTR and cystic fibrosis.